Abstract
A systematic review was conducted to evaluate the effectiveness of initiating insulin treatment with insulin glargine or insulin detemir for type 2 diabetes in a routine clinical practice setting. Medline, EMBASE and Cochrane literature databases were searched to identify published “real world” reports. Studies were included in the review if they reported the following; insulin dose, change in HbA1c, change in body weight and hypoglycemic events. In routine practice, decreases in HbA1c associated with insulin glargine and insulin detemir were variable and ranged between approximately -0.3% to -1.5% depending on prior treatment, but switching to insulin analogs was associated with less weight gain than previously reported. Compared with data reported in published trials, hypoglycemic event rates associated with basal analog insulin use in clinical practice were lower in patients initiating insulin and comparable in patients using basal-bolus regimens. Most patients were treated with low doses of insulin analog administered as once daily injections. In routine clinical practice most patients stopped concomitant use of sulfonylureas when initiating insulin analogs and it is likely that this together with the lower dose of insulin influenced outcomes. Nevertheless, despite initiating insulin therapy, it was also apparent that for many patients in routine clinical practice attainment of glycemic goals remains elusive.
Keywords: HbA1c, Hypoglycemia, Insulin Detemir, Insulin Glargine, Real-World Studies, Weight Gain, OADs, Neutral Protamine Hagedorn, RCTs, glargine, levemir, lantus, basal-bolus regimen, nocturnal hypoglyce-mia, insulin dose, change in HbA1c, change in weight, incidence of hypoglycemia, sulfonylureas, insulin lispro, Basal Insulin Detemir Regimens, thiazolidinediones, basal-bolus, major hypoglycemia, nocturnal hypogly, OAD regimens
Current Diabetes Reviews
Title: Long-Acting Insulin Analogs: A Review of “Real-World” Effectiveness in Patients with Type 2 Diabetes
Volume: 7 Issue: 1
Author(s): Richard F. Pollock, Katrina M. Erny-Albrecht, Anupama Kalsekar, David Bruhn and William J. Valentine
Affiliation:
Keywords: HbA1c, Hypoglycemia, Insulin Detemir, Insulin Glargine, Real-World Studies, Weight Gain, OADs, Neutral Protamine Hagedorn, RCTs, glargine, levemir, lantus, basal-bolus regimen, nocturnal hypoglyce-mia, insulin dose, change in HbA1c, change in weight, incidence of hypoglycemia, sulfonylureas, insulin lispro, Basal Insulin Detemir Regimens, thiazolidinediones, basal-bolus, major hypoglycemia, nocturnal hypogly, OAD regimens
Abstract: A systematic review was conducted to evaluate the effectiveness of initiating insulin treatment with insulin glargine or insulin detemir for type 2 diabetes in a routine clinical practice setting. Medline, EMBASE and Cochrane literature databases were searched to identify published “real world” reports. Studies were included in the review if they reported the following; insulin dose, change in HbA1c, change in body weight and hypoglycemic events. In routine practice, decreases in HbA1c associated with insulin glargine and insulin detemir were variable and ranged between approximately -0.3% to -1.5% depending on prior treatment, but switching to insulin analogs was associated with less weight gain than previously reported. Compared with data reported in published trials, hypoglycemic event rates associated with basal analog insulin use in clinical practice were lower in patients initiating insulin and comparable in patients using basal-bolus regimens. Most patients were treated with low doses of insulin analog administered as once daily injections. In routine clinical practice most patients stopped concomitant use of sulfonylureas when initiating insulin analogs and it is likely that this together with the lower dose of insulin influenced outcomes. Nevertheless, despite initiating insulin therapy, it was also apparent that for many patients in routine clinical practice attainment of glycemic goals remains elusive.
Export Options
About this article
Cite this article as:
F. Pollock Richard, M. Erny-Albrecht Katrina, Kalsekar Anupama, Bruhn David and J. Valentine William, Long-Acting Insulin Analogs: A Review of “Real-World” Effectiveness in Patients with Type 2 Diabetes, Current Diabetes Reviews 2011; 7 (1) . https://dx.doi.org/10.2174/157339911794273892
DOI https://dx.doi.org/10.2174/157339911794273892 |
Print ISSN 1573-3998 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6417 |
Call for Papers in Thematic Issues
Advancing Diabetic Wound Healing: Mechanisms and Interventions
In recent years, diabetic wounds have become a global health concern with the increase in the incidence of diabetes. Diabetic wounds are a kind of chronic and refractory ulcer. It is generally due to the microcirculatory disturbances and the reduced levels of endogenous growth factors. Delayed cutaneous wound healing is ...read more
Oxidative and inflammatory responses in the development of secondary diabetic complications
Diabetes, along with its associated secondary complications, represents a significant global health challenge, contributing significantly to morbidity and mortality. Unhealthy lifestyle habits, reduced physical activity, environmental pollutants, and stress are pivotal factors in the onset of diabetes, particularly type-2 diabetes. Poorly managed hyperglycemia can lead to various complications, including neuropathy, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
From Brain Ischemia-Reperfusion Injury to Possible Sporadic Alzheimers Disease
Current Neurovascular Research Prevalence and Associates of Foot Deformities among Patients with Diabetes in Jordan
Current Diabetes Reviews PDE5 Inhibitors: In Vitro and In Vivo Pharmacological Profile
Current Pharmaceutical Design Editorial (Thematic issue: Possible Therapeutic Targets for the Treatment of Diabetic Retinopathy: Evidences from Experimental Models)
Current Clinical Pharmacology β-Amyloid, Cholinergic Transmission, and Cerebrovascular System - A Developmental Study in a Mouse Model of Alzheimer's Disease
Current Pharmaceutical Design Novel Targeting of Apoptosis Pathways for Prostate Cancer Therapy
Current Cancer Drug Targets Cardiac Biomarkers in the Identification of Future Risk in Chronic Obstructive Pulmonary Disease
Current Topics in Medicinal Chemistry Prolonged Adrenal Insufficiency After the Discontinuation of Mitotane Therapy
Endocrine, Metabolic & Immune Disorders - Drug Targets The Physiological Characteristics and Transcytosis Mechanisms of the Blood-Brain Barrier (BBB)
Current Pharmaceutical Biotechnology Patents Review in siRNA Delivery for Pulmonary Disorders
Recent Patents on Drug Delivery & Formulation The Attentional Set-Shifting Test Paradigm in Rats for the Screening of Novel Pro-Cognitive Compounds with Relevance for Cognitive Deficits in Schizophrenia
Current Pharmaceutical Design PCSK9 Inhibition - A Novel Mechanism to Treat Lipid Disorders?
Current Pharmaceutical Design Nebulizable Cycloserine Loaded PLGA Nanoparticles: Formulation Design, in vitro Evaluation and Stability Studies
Current Nanomedicine Implications of Dietary Leucine on Muscle mTOR Gene Expression and Redox Status in Rats Following High Intensity Effort
Current Nutrition & Food Science Dynamics of Toll-like Receptors Signaling in Skeletal Muscle Atrophy
Current Medicinal Chemistry Trans-Resveratrol: A Magical Elixir of Eternal Youth?
Current Medicinal Chemistry Perioperative Considerations in Diabetic Patients
Current Diabetes Reviews Cardio-vascular Activity of Catestatin: Interlocking the Puzzle Pieces
Current Medicinal Chemistry Platelet Protein Synthesis and Translational Control
Current Proteomics CYP Epoxygenase Derived EETs: From Cardiovascular Protection to Human Cancer Therapy
Current Topics in Medicinal Chemistry